We describe a patient in a skilled nursing facility who had symptom exacerbation of bipolar disorder while taking divalproex and olanzapine. The patient was treated with a combination of aripiprazole and divalproex after discontinuation of olanzapine.
Studies document the presence of manic symptoms in 6.5% to 18% of elderly depressed individuals. 2 There is an increasing awareness among primary care physicians about the importance of screening for and treating bipolar disorder in patients who present with depressive symptoms. This case highlights the use of agents other than divalproex, lithium, and olanzapine in the treatment of bipolar illness. Aripiprazole, referred to as a dopamine system stabilizer (D 2 partial agonist/antagonist), is one such agent that may be used. Although the drug has not yet received approval for treatment of bipolar illness from the U.S. Food and Drug Administration (FDA), clinical trials have demonstrated efficacy in young adults. 3, 4 Studies in older adults are usually done as a follow-up to studies in younger adults.
In a phase 3, multicenter, double-blind study (study 1), 5 262 patients with acute mania were randomized to treatment with aripiprazole, 30 mg, (N = 130) or placebo (N = 132) for 3 weeks. Aripiprazole produced a statistically significant improvement in Young Mania Rating Scale scores beginning on day 4 (p < .005), which was maintained throughout the 3-week study. Twice as many aripiprazole-treated patients responded to treatment compared with placebo-treated patients (40% vs. 19%, respectively; p = .01). 5 Discontinuations due to adverse events were similar between the aripiprazole and placebo groups (11% and 13%, respectively). Aripiprazole was efficacious, safe, and well tolerated in patients with bipolar disorder experiencing an acute manic or mixed episode. Additional trials have been conducted but have not yet been published in the peer-reviewed literature. The improvement in Ms. A's Parkinson's disease symptoms was an incidental finding. The improvement in parkinsonian symptoms may be the result of partial agonist activity of aripiprazole at the dopamine receptor.
Recently, risperidone and quetiapine were granted FDA approval for the treatment of acute mania. Olanzapine has received FDA approval for maintenance treatment in addition to the acute mania indication. It is probable that aripiprazole might have an acute mania indication, thus increasing the number of safe treatment options available in the primary care setting for geriatric patients with bipolar disorder. Aripiprazole is not a sedating medication and has not been noted to worsen cognition. Aripiprazole is well tolerated, and there are no clinically significant drug-drug interactions of concern with the combination of multiple medications Ms. A was taking either prior to or after the switch to aripiprazole. In addition, it is our opinion that drug-drug interactions were not a reason for lack of efficacy of olanzapine. In older adults taking multiple medications, drug-drug interactions are a potential concern, as these medications for bipolar disorder are prescribed longterm. Bipolar disorder is a lifelong condition and requires long-term medication treatment. Otherwise, there is a high risk of relapse.
This clinical case demonstrates that there are now newer agents available for the management of bipolar disorder, although some are being used off-label at this time. 
